The World Health Organization recommended against using Gilead Sciences Inc.’s remdesivir to treat hospitalized Covid-19 patients less than a month after U.S. regulators granted the drug a speedy approval, reports Bloomberg.
Huge blow to the drug
“There is currently no evidence that it improves survival or the need for ventilation,” a panel of WHO-convened experts developing Covid-19 treatment guidelines said in The BMJ medical journal.
The recommendation is a blow to Gilead’s drug, which was one of the first thought to offer a meaningful benefit to coronavirus patients after a study showed it reduced their recovery time. The antiviral has been used widely to treat Covid and was among the drugs President Donald Trump received when he was diagnosed with the disease in early October.
Gilead shares fell as much as 1.9% in New York. They have lost 8% this year.
The experts made the recommendation after the results of a global trial sponsored by the WHO, called Solidarity, found last month that remdesivir didn’t reduce deaths.
They also reviewed data from three other trials and said the drug “has no meaningful effect” on the time it took patients to clinically improve.
WHO’s trial in question?
The Solidarity results were published on Oct. 15. The U.S. Food and Drug Administration approved the drug a week later, basing its decision on a trial run by the National Institutes of Health that showed remdesivir reduced hospitalized patients’ recovery time by five days.
Gilead has questioned the results of WHO’s trial and said the agency still has not released key data to allow the company or others to evaluate the reliability of the interim results.
Despite the discordance with the WHO, the FDA said in its review of remdesivir that “there were no issues identified that would benefit from discussion” by a panel of outside advisers.
On Thursday evening, U.S. regulators doubled down on their support for the antiviral.
The FDA granted an emergency use authorization for remdesivir in combination with baricitinib, a rheumatoid arthritis treatment from Eli Lilly & Co. and Incyte Corp., for hospitalized Covid-19 patients requiring supplemental oxygen or ventilation.
Solidarity trial not controlled well
Lilly Chief Executive Officer David Ricks pushed back on the WHO recommendation against remdesivir. “We know the benefits of remdesivir are probably subtle, or modest, and the benefits of baricitinib on top of remdesivir are probably incremental,” he said in an interview with CNBC on Friday.
The Solidarity trial was “not very well controlled,” Ricks said, and the NIH took a more calculated approach to conduct highly controlled clinical trials that account for these incremental benefits, and thus, were relying on different data. “A lot of progress is made in medicine in improving outcomes through incremental advances,” he said.
“This decision by the WHO throws some confusion out there,” he said. “But personally, our view in our industry is to use better-controlled studies to evaluate the benefits of medicines.”
The drug is still used by many countries
The FDA originally granted emergency use authorization to remdesivir in May. Gilead requested full FDA approval in August.
The European Commission granted the drug conditional authorization in July based on the U.S.-led clinical trial.
Other countries have also approved remdesivir as a treatment for Covid. Japan’s chief cabinet secretary, Katsunobu Kato, said Friday there’s no need for the nation, which gave its nod in May, to review remdesivir’s approval at this time.
Zhong Nanshan, a Chinese expert on infectious disease, said at a conference in Zhuhai that remdesivir isn’t “entirely useless,” citing shortened hospital stays among mild patients in the U.S.
The WHO experts wrote in The BMJ that their findings shouldn’t be interpreted to mean that remdesivir is ineffective, but that “there is no evidence-based on currently available data that it does improve patient-important outcomes.”
Did you subscribe to our daily newsletter?
It’s Free! Click here to Subscribe!
Source: Bloomberg
